Alnylam Pharmaceuticals, Inc.

And thank you for standing by. Welcome to the Al Nilem Pharmaceuticals Second Quarter 2024 conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a Q&A session. Please be advised that today's conference is being recorded. And I would now like to hand the conference over to the company for their remarks. Please go ahead.

Good morning. I'm Christine Lindenboom, Senior Vice President of Investor Relations and Corporate Communications at Al Nilem. With me today are Yvonne Greenstreet, Chief Executive Officer, Tova Tangular, Chief Commercial Officer, Pushkal Garg, Chief Medical Officer, and Jeff Poulton, Chief Financial Officer. For those of you participating via conference call, the accompanying slides can be accessed by going to the events section of the investors page of our website, investors.onilam.com slash events. During today's call, as outlined in slide two, Yvonne will offer introductory remarks and provide some general context. Togo will provide an update on our global commercial progress, Pusha will review pipeline updates and clinical progress, and Jeff will review financial and guidance, followed by a summary of upcoming milestones before we open the call for your questions. I would like to remind you that this call will contain remarks concerning El Nilo's future expectations, plans, and prospects, which constitute forward-looking statements for the purposes of the Safe River Provision under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in our most recently periodic report on file of the SEC. In addition, any forward-looking statements represent our views only of the date of this reporting and should not be relied upon as representing our views of any subsequent date. We specifically disclaim any obligation to update such statements. With that, I'd like to turn the call over to Yvonne. Yvonne?

Thanks, Christine, and thank you, everyone, for joining the call today. The second quarter of 2024 was a transformative one for our nylon. Commercially, we achieved 34% year-over-year growth in global net product revenues, generating $410 million in net product revenues, which was primarily driven by 37% year-over-year growth in our TTR business. And as such, we've raised our revenue guidance for the year by 11% as a midpoint. The commercial capability that we've established over the last five years will continue to drive significant growth for our current business and will be a key to our success as we prepare for a potential launch next year in ATTR cardiomyopathy. To that end, the major highlight of Q2 was our announcement of positive top-line results in the Helios B phase 3 study of Vutriceran in ATTR cardiomyopathy, showing that Vutriceran improved cardiovascular outcomes, including a 35% to 36% mortality benefit compared to placebo, and demonstrated encouraging safety. These results reflect the true power of the RNAi mechanism of action, supporting what we believe to be a highly differentiated therapeutic profile. and positioned Futrisram as the new standard of care in ATTR cardiomyopathy, assuming regulatory approval. Moreover, we believe these positive results can establish Futrisram as an anchor commercial franchise for our nylon, driving robust top-line growth and value creation for many years to come. With an eye towards our nylon pizza fest by 25 goals, we are firm in our belief that we are on track to become a top-tier biotech, developing and commercializing transformative medicines for patients around the world with rare and prevalent diseases, driven by a high-yielding pipeline of first and all best-in-class product candidates from our organic product engine, all while delivering exceptional financial results. Before I turn it over to Tolga, I'm excited to tell you about a TTR Investor Day that we will be hosting in New York City on Wednesday, October the 9th. This event, which will be webcast live, will focus on our leadership in ATTR amyloidosis, including the efforts that we are undertaking to optimize the success of the launch of Ambutra in ATTR cardiomyopathy. You'll hear from several of my Arnylam colleagues, as well as external experts. We'll be sharing more details about this event shortly, and I hope that you can join us in New York on October the 9th. With that, let me now turn the call over to Tolga for a review of our commercial performance. Tolga?